IPP Bureau
SRL Diagnostics opens state-of-the-art laboratory in Jamshedpur
By IPP Bureau - April 26, 2022
The new lab in the industrial town is SRL’s 4th lab in the state of Jharkhand
Sygnature Discovery acquires Peak Proteins
By IPP Bureau - April 26, 2022
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
GSK launches once daily, single inhaler-triple therapy for COPD patients
By IPP Bureau - April 26, 2022
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Differentiation based on innovation is the way forward: S Aparna
By IPP Bureau - April 26, 2022
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
Drugs Controller clears Covaxin, Corbevax and ZyCov-D for kids
By IPP Bureau - April 26, 2022
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
Corbevax gets DCGI nod for Emergency Use in 5-12 years
By IPP Bureau - April 26, 2022
The approval comes soon after Corbevax was given the nod for 12-15-year group
DCGI grants Covaxin Emergency Use Approval for children 6-12 years
By IPP Bureau - April 26, 2022
Covaxin was earlier approved for children 12-18 years of age
ZyCoV-D two-dose vaccine receives Emergency Use Approval from DCGI
By IPP Bureau - April 26, 2022
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Bachem partners with Eli Lilly on oligonucleotide-based APIs
By IPP Bureau - April 26, 2022
Under the terms of the agreement, Bachem will provide the appropriate engineering infrastructure and expertise to implement Lilly’s novel oligonucleotide manufacturing technology
CanSinoBIO rebrands to reflect commitment to life sciences research
By IPP Bureau - April 25, 2022
This is the first major brand refresh of CanSinoBIO since its inception in 2009
Global AYUSH meet ends with promise of Rs 9000 cr. in investment
By IPP Bureau - April 25, 2022
Investment and innovation opportunities in the field of AYUSH are limitless : Sarbananda Sonowal
Shionogi’s once-a-day Covid-19 anti-viral shows rapid virus clearance
By IPP Bureau - April 25, 2022
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
By IPP Bureau - April 25, 2022
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Glenmark is the first to launch Teneligliptin and Pioglitazone Fixed-Dose Combination
By IPP Bureau - April 25, 2022
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Aleor Dermaceuticals receives USFDA approval for Clobestasol
By IPP Bureau - April 25, 2022
Clobetasol Propionate Foam, 0.05% has an estimated market size of US $ IO million for twelve months ending Dec 2021 according to IQVIA
